Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of CAEL-101 plus plasma cell dyscrasia therapy versus placebo plus plasma cell dyscrasia therapy in treatment-naive Mayo stage IIIb AL amyloidosis
CTR20230662Phase 3Active
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in light-chain amyloidosis comparing CAEL-101 + plasma cell dyscrasia therapy with Placebo + plasma cell dyscrasia therapy (2 arms). Primary endpoints: Overall survival and cardiovascular hospitalization frequency and Safety and tolerability. Started May 2023; status: active.
02
Drugs
anselamimab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on CTR20230662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230662.